Status:
TERMINATED
Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The symptoms of respiratory distress caused by COVID-19 may be reduced by drugs combining anti-inflammatory and antiviral effects. This dual effect may simultaneously protect severely-ill patients and...
Detailed Description
Coronavirus Disease 2019 (COVID-19) is due to SARS-CoV-2 infection. (1,2) The exacerbated inflammatory response in COVID-19 infected critically ill patients calls for appropriate anti inflammatory the...
Eligibility Criteria
Inclusion
- COVID-19 infected patient
- Age 18 years or older
- Presence of pneumonia
- PaO2/FiO2 \< 300 mm Hg or SpO2 \< 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in \[94-98%\] or lung infiltrates \> 50%
- Medical insurance
Exclusion
- Presence of do-not-resuscitate order
- Pregnancy
- Prisoners
- Known Naproxen allergy or intolerance
- Severe renal failure
Key Trial Info
Start Date :
April 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04325633
Start Date
April 24 2020
End Date
December 15 2020
Last Update
February 25 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Réanimation médico-chirurgicale, Avicenne Hospital
Bobigny, France, 93000
2
Urgences, Avicenne Hospital
Bobigny, France, 93000